mk-8776 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

mk-8776 has been researched along with Leukemia--Myelogenous--Chronic--BCR-ABL-Positive* in 1 studies

Other Studies

1 other study(ies) available for mk-8776 and Leukemia--Myelogenous--Chronic--BCR-ABL-Positive

ArticleYear
Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells.
    Leukemia research, 2018, Volume: 64

    Drug resistance to tyrosine kinase inhibitors (TKIs) is currently a clinical problem of chronic myelogenous leukemia (CML). Bcr-Abl protein depletion is considered as a way to overcome drug resistance to TKIs. In our study, Chk1 inhibitors, AZD7762 and MK-8776, had strong antitumor effects on CML cell line KBM5 and imatinib-resistant form KBM5

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Pyrazoles; Pyrimidines; Thiophenes; Urea; Xenograft Model Antitumor Assays

2018